Thyrocare Technologies Ltd - 539871 - Outcome of Board Meeting
Kindly note that the Board Meeting held today to consider and approve unaudited financial results of the Company (both Stand-alone and Consolidated) for the quarter/half year ended 30-09-2019, commenced at 17.30 hrs and ended at 19.00 hours. Thyrocare Technologies Ltd - 539871 - Unaudited Financial Results For The Quarter / Half Year Ended 30Th September 2019
This is to inform you that the Board of Directors of the Company, at their meeting held today, approved the unaudited Financial Results (Stand-alone and Consolidated) for the Quarter / Half year ended September 30, 2019. The Board of Directors have also approved payment of interim dividend for the financial year 2019-20, at the rate of Rs. 5.00 (Rupees Five only) per share (50% of the face value of Rs. 10/- each). The Stand-alone and Consolidated unaudited financial results for the quarter / half year ended September 30, 2019, along with the Limited Review Reports, are attached pursuant to Regulation 33 (3) (a) to (c) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Further we hereby declare that the statutory auditors have issued unmodified opinion on both the Stand-alone and Consolidated Financial Results. This is to inform that the meeting commenced at 17.30 hours and ended at 18.30 hours today, the 7th November, 2019. Thyrocare Technologies Ltd - 539871 - Unaudited Financial Results For The Quarter / Half Year Ended 30Th September 2019
This is to inform you that the Board of Directors of the Company, at their meeting held today, approved the unaudited Financial Results (Stand-alone and Consolidated) for the Quarter / Half year ended September 30, 2019. The Board of Directors have also approved payment of interim dividend for the financial year 2019-20, at the rate of Rs. 5.00 (Rupees Five only) per share (50% of the face value of Rs. 10/- each). The Stand-alone and Consolidated unaudited financial results for the quarter / half year ended September 30, 2019, along with the Limited Review Reports, are attached pursuant to Regulation 33 (3) (a) to (c) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Further we hereby declare that the statutory auditors have issued unmodified opinion on both the Stand-alone and Consolidated Financial Results. This is to inform that the meeting commenced at 17.30 hours and ended at 18.30 hours today, the 7th November, 2019. Thyrocare Technologies Ltd - 539871 - Outcome of Board Meeting
This is to inform you that the Board of Directors of the Company, at their meeting held today, approved the unaudited Financial Results (Stand-alone and Consolidated) for the Quarter / Half year ended September 30, 2019. The Board of Directors have also approved payment of interim dividend for the financial year 2019-20, at the rate of Rs. 5.00 (Rupees Five only) per share (50% of the face value of Rs. 10/- each). The Stand-alone and Consolidated unaudited financial results for the quarter / half year ended September 30, 2019, along with the Limited Review Reports, are attached pursuant to Regulation 33 (3) (a) to (c) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Further we hereby declare that the statutory auditors have issued unmodified opinion on both the Stand-alone and Consolidated Financial Results. This is to inform that the meeting commenced at 17.30 hours and ended at 18.30 hours today, the 7th November, 2019. Thyrocare Technologies Ltd - 539871 - Board Meeting Intimation for 1. Unaudited Financial Results (Stand-Alone And Consolidated) For The Quarter/Half Year Ended 30-09-2019. 2. Interim Dividend, If Any. 3. Other Subjects, If Any.
Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2019 ,inter alia, to consider and approve Pursuant to Regulation 29 (1) (a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to intimate that a meeting of our Board of Directors of the Company will be held on Thursday, November 07, 2019, at the Corporate Office of the Company, inter alia, to consider and approve Unaudited Stand-alone and Consolidated Financial Results of the Company for the quarter / half year ended September 30, 2019 and to consider payment of interim dividend, if any. Intimation of the above meeting of the Board of Directors is also being published in newspapers, as required under Regulation 47 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. Thyrocare Technologies Ltd - 539871 - Compliance Certificate For The Quarter Ended 30-09-2019 Under Regulation 40 (9) Of Securities & Exchange Board Of India (Listing Obligations & Disclosure Requirements) Regulations, 2015.
We are filing herewith Compliance Certificate dated 17-10-2019 issued by Mr. V. Suresh, Practising Company Secretary, pursuant to the Regulation 40 (9) of Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the Half-year ended September 30, 2019. Please take the same on record. Thyrocare Technologies Ltd - 539871 - Compliance - Compliance Certificate For The Quarter Ended 30-09-2019 Under Regulation No. 7 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
As per the requirement of Regulation 7 (3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that activities in relation to both physical and electronic share transfer facility are maintained during the period April 1, 2019 to September 30, 2019 (both days inclusive) by the Company's Registrar and Share Transfer Agent, viz., Link Intime India Private Limited, which is registered as Registrar & Share Transfer Agent in Category-I with the Securities and Exchange Board of India vide Registration Number : INR000004058. Thyrocare Technologies Ltd - 539871 - Shareholding for the Period Ended September 30, 2019
Thyrocare Technologies Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2019. For more details, kindly Click here Thyrocare Technologies Ltd - 539871 - Statement Of Investor Complaints For The Quarter Ended September 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Ramjee DoraiDesignation :- Company Secretary and Compliance Officer Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that we would be having a Con-call with the representative(s) of Capital Investment Research Services Private Limited, at 05.30 P.M. on Friday, October 04, 2019. Please note that this is subject to any last minute changes.